Treatments for Asia-Prevalent Cancers
Total Trials
1
As Lead Sponsor
As Collaborator
0
Total Enrollment
120
NCT05462236
MNK Inhibitor AUM001 in Combination With Either Pembrolizumab or Irinotecan to Treat Metastatic Colorectal Cancer
Phase: Phase 2
Role: Lead Sponsor
Start: Apr 14, 2023
Completion: Oct 15, 2026
Loading map...